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Abstract
Chronic and acute tendon injuries are frequent afflictions, for which treatment is 
often long and unsatisfactory. When facing extended injuries, matrices and scaffolds 
with sufficient biomechanical properties are required for surgical repair and could 
additionally serve as supports for cellular therapies to improve healing. In this study, 
protocols of either commonly used detergents only (SDS 1%, Triton 1%, TBP 1%, 
and Tween‐20 1%) or a combination of freeze/thaw (F/T) cycles with decellulari-
zation agents (NaCl 1M, ddH2O) were evaluated for the decellularization of horse 
equine superficial digital flexor tendon (SDFT) for hand flexor or extensor tendon 
reconstruction. Decellularization efficiency was assessed microscopically by histo-
logical staining (HE, DAPI) and DNA quantification. Macroscopical structure and 
biomechanical integrity of the tendon matrices were further assessed by gross obser-
vation, histological staining (SR), and mechanical testing (ultimate strain and stress, 
Young’s modulus, energy to failure) for select protocols. Decellularization with hy-
pertonic NaCl 1M in association with F/T cycles produced the most robust tendon 
matrices, which were nontoxic after 10 days for subsequent recellularization with 
human fetal progenitor tendon cells (hFPTs). This standardized protocol uses a less 
aggressive decellularization agent than current practice, which allows subsequent re-
seeding with allogenic cells, therefore making them very suitable and bioengineered 
tendon matrices for human tendon reconstruction in the clinic.
K E Y W O R D S
cell therapy, decellularization, extracellular matrix, hand flexor tendons, human fetal progenitor 
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1 |  INTRODUCTION
Hand tendon injuries are a frequent challenge for the hand 
surgeon that often require surgical grafting for proper repair.1 
While autograft remains the ideal choice, donor‐site morbid-
ity and potential lack of material are limiting.2 Alternative 
matrices from biological or synthetic sources must then be 
considered for tendon grafts, providing that the resulting 
scaffolds are biocompatible, retain sufficient mechanical 
properties, and have potential for cellular reseeding.
Decellularized extracellular matrix (ECM) scaffolds 
prepared from tissues of human or animal sources are a 
potential option that have presented encouraging results 
for tendon allograft or xenograft.3 However, grafts directly 
obtained from allogenic tendon tissue have produced ei-
ther lower biomechanical properties than native tendon or 
are associated with much higher costs than autografts.4‒7 
Several studies of commercially available tendon grafts 
have reported their biological characteristics and clinical 
efficacy, but tendon matrices specifically designed for hand 
tendons are currently unavailable.6,8‒10 The use of animal 
tendon as a source material for this purpose could lead to 
an ideal matrix with better overall mechanical properties, 
and strategies have been tested to process tendon of vari-
ous species, including rat,11 porcine,12,13 canine, rabbit,14,15 
and equine.16,17 The equine superficial digital flexor tendon 
(SDFT) presents a potential realistic source for human ten-
don grafting due to its large dimensions, availability in large 
quantities, and traceability through accredited food indus-
tries. Equine tissue is also known to be less immunogenic 
than other species, such as bovine.18 With an increase in 
security for disease transmission, this source could be val-
orized from an ecological point of view in the recycling of 
waste material for unmet biomedical needs.
All biological tendon sources must be efficiently decel-
lularized prior to grafting with a treatment strong enough to 
eliminate cellular material while conserving the initial struc-
ture and mechanical properties of the tissue.19 Detergents, 
such as sodium dodecyl sulfate (SDS) and t‐octyl‐phenoxy-
polyethoxyethanol (Triton X‐100), tri‐n‐butyl phosphate 
(TBP), or Tween‐20, are often used to solubilize cell mem-
branes.11,20,21 Enzymes, such as trypsin and collagenase, can 
also be used in processing, but may result in undesired ECM 
breakdown that would compromise tendon repair.22 Physical 
treatments can further aid in decellularization and the pene-
tration of chemical agents into deeper tissue regions of the 
ECM. Indeed, freeze‐thaw (F/T) cycling coupled with deter-
gents has been shown to increase the decellularization effi-
ciency of large tendons.16 However, any chemical or enzymes 
used for decellularization must be thoroughly removed from 
the matrix, which can incur additional processing time com-
pared to neutral solutions, such as NaCl or water, which have 
also been used for human skin and tissue processing.23
Correct matrix processing would ensure the conservation 
of proteins24 and growth factors,25 therefore promoting heal-
ing by cell adhesion and migration and the interaction with 
host tissue.24 During the last decade, biologics and cellular 
therapies have become of interest as potential alternative 
treatments for tendon injuries to aid in this healing process, 
and F/T treatment has been shown to be biocompatible with 
equine adipose‐derived stromal cells.16,26 We have previously 
evaluated the characteristics of human fetal progenitor teno-
cytes (hFPTs) in vitro and have obtained promising results 
with this cell source.27 For chronic tendinopathies or simple 
lacerations, we have also investigated the use of hFTPs in an 
injectable, hyaluronic acid gel preparation to locally deliver 
these cells and potentially accelerate the healing process in 
small tendon defects.28
The aim of this study was to select an efficient decellu-
larization method for equine tendon that retained the me-
chanical properties and functionality of the tendon, as well as 
that would support biocompatibility with subsequent cellular 
therapies. We show that harsh detergents are not necessary 
for effective decellularization and, for the first time, demon-
strate the biocompatibility of SDFT with human cellular 
therapy using hFPTs. We present an optimized, simple, and 
cost‐effective processing using F/T cycles and NaCl that can 
be implemented for clinical preparation of tendon grafts for 
tendon reconstruction.
2 |  MATERIALS AND METHODS
2.1 | Equine tendon source, processing, and 
conservation
Horse superficial digital flexor tendons (SDFT) were ob-
tained from Profil Export (Chavrieu Chavagneux, France) 
with traceability for each source animal. Tendons were har-
vested, cleaned, and trimmed to standard dimensions, then 
put into hermetic bags, frozen immediately, and transferred 
to our unit, where they were stored at −80°C until further use. 
The tendons were later thawed at room temperature (RT) in 
order to facilitate the removal of surrounding tissue and epi-
tenon with a scalpel and subsequently frozen at −20°C to ob-
tain sufficient rigidity for processing into pieces of 150 mm × 
10 mm. Thin slices of 1.2 mm thickness were then prepared 
with a dermatome (Aesculap AG, Tuttlingen, Germany) and 
conserved at −80°C.
2.2 | Decellularization of standardized 
tendon tissue samples
The standardized tendon tissues were further cut to obtain 
pieces of 20 mm × 10 mm × 1.2 mm for decellulariza-
tion. Two types of decellularization protocols were tested, 
using either common detergents alone or F/T cycles with a 
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decellularizing agent. The first group tested commonly used 
detergent treatments: SDS 1% (Ambion, ThermoFischer 
Scientific, Waltham, MA, USA), Triton 1% (Applichem, 
Darmstadt, Germany), TBP 1% (Sigma‐Aldrich, Darmstadt, 
Germany), or Tween‐20 1% (Applichem). Chemical decel-
lularization was performed by immersion of tendons in solu-
tions with constant stirring at 300 RPM for 48 hours. The 
tendon tissues were then washed twice for 15 minutes in 
ddH2O.
The second decellularization protocol consisted of com-
bined F/T with neutral solutions of hypertonic NaCl 1M 
(Sigma‐Aldrich), hypotonic ddH2O, or Triton 1%. A mod-
ified version of F/T decellularization described by Roth 
et al29 was used, where samples were submitted to five cy-
cles of 2‐minute freezing in liquid nitrogen and 10 minutes 
at 37°C in 1X phosphate‐buffered saline (PBS; Interlaken, 
Switzerland). Samples were then incubated 48 hours at 
RT in ddH2O followed by 48 hours of incubation in NaCl 
1M or ddH2O. Afterward, samples were washed twice for 
15 minutes in ddH2O and 24 hours in DMEM (Dulbecco’s 
modified Eagle medium, ThermoFischer Scientific) supple-
mented with 10% fetal bovine serum (Gibco Qualified FBS, 
ThermoFischer Scientific).
All samples were kept in 1X PBS supplemented with 
1% penicillin‐streptomycin (Pen Strep, ThermoFischer 
Scientific) until further analysis.
2.3 | DNA quantification of decellularized 
tendon matrix
For all samples and controls, 25‐35 mg of tissue was minced 
into 1‐mm3 pieces and dehydrated at 60°C overnight. The 
tissues were then digested with proteinase K and purified, 
according to manufacturer instructions (NucleoSpin Tissue 
kit, Macherey‐Nagel, Düren, Germany). DNA quantifi-
cation was measured by spectrophotometry (Nanodrop 
1000, ThermoFischer Scientific). Each quantification was 
repeated in triplicate with samples from different tendons 
(n  =  3) and treatments were compared using a 2‐tailed 
two‐sample t‐test compared to control, nondecellularized 
tendons.
2.4 | Histology of standardized 
decellularized tendon matrix
A 5 mm × 5 mm × 1.2 mm piece of tendon matrix from each 
treatment was fixed in 4% (w/v) neutralized formalin solu-
tion (J.T. Baker, Deventer, The Netherlands) for 24 hours 
at RT, washed thrice in PBS, and subsequently dehydrated 
and embedded in paraffin (Merck Millipore, Darmstadt, 
Germany). Sections of 5 µm in length were excised and 
sections corresponding to the middle depth were taken for 
staining. Each tendon matrix was stained with hematoxylin 
and eosin (HE), 4ʹ,6‐diamidino‐2‐phenylindole (DAPI), or 
Sirius Red (SR). Histology images were taken with a Leica 
DM 5500 microscope equipped with a CMOS Camera DMC 
2900 Color for HE and SR sections and with a CCD Camera 
DFC 3000 B/W for DAPI fluorescent staining. SR sections 
images were taken under polarized light to determine col-
lagen fiber orientation.
At this point, the protocol producing the best resulting 
matrix samples in terms of decellularization and biological 
properties was selected for further testing. Select detergent 
protocols representing the most widely used methods (SDS 
1% and Triton 1%) were retained for comparison.
2.5 | Biomechanical testing of native 
tendon and decellularized tendon matrices
Biomechanical tests were performed on tendon slices 
(150 mm × 10 mm × 1.2 mm; Figure 1A) treated with 
selected protocols, and measures were taken with an 
Electropuls Dynamic Test System (Instron E3000; Instron, 
Norwood, MA, USA; Figure 1B). We developed a system 
for stable fixation to avoid slippage before rupture in col-
laboration with the Institute of Mechanical Engineering at 
EPFL in order to create an optimal system compared to 
published methods.30‒34 Tendons were attached with the 
aid of two clamps specifically designed with a zigzag pat-
tern to increase fixation while preventing weakening of the 
structure around clamps for tendon testing (Figure 1D). 
No slippage was observed during the measurements. The 
length of tendons was standardized at 150 mm, which was 
suitable for a distance of approximately 80 mm between 
clamps and more than 30 mm of grip on each side for good 
fixation. A sufficient length between the clamps was used 
in order to diminish the impact of end effects known to 
occur in the analysis of soft tissues.35,36 A precharge of 5N 
was applied to the tissue, and the new position was defined 
as the origin; the gap was considered as the initial length 
and the elongation and force were set to zero. A rate of 
25 mm/min was used to gradually put the tendon under 
tension until rupture (Figure 1C). The force and elonga-
tion were recorded every 20 milliseconds and normalized 
to stress and strain. Strain (%) was determined by dividing 
the deformation at each measure point by the initial length. 
Stress (MPa) was determined by dividing the force with 
the initial cross section of the sample. An example of the 
typical stress‐strain curve is shown in Figure 2E. Stress and 
strain allowed normalization of the results and determina-
tion of Young’s modulus by calculating the slope of the 
stress‐strain regression curve in its linear region, between 
2% and 4% of strain prior to failure. The energy to failure 
was calculated by integration with the rectangle method for 
each measure of force and elongation. For each parameter, 
an F test was done to compare variances and the Student’s 
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F I G U R E  1  Tensile testing of tendon slides. A, Example of tendon slices of 150 mm × 10 mm × 1.2 mm used for tensile testing. B, Instron 
tensil machine used for the mechanical measurements. The tendon band is fixed between the two clamps, one of which is attached to a force captor 
(visible at the bottom). C, Example of tendon being stretched until rupture. D, Detailed pattern of the clamps designed for the evaluation of tendon 
within this study. E, Typical curve obtained with stress versus strain plot for tendon biomechanics. Toe region corresponds to the strain where 
collagen becomes aligned to create tension. In the linear region, collagen fibers are aligned and further strain provokes higher stress until rupture. 
Physiological strain is usually situated between 2% and 6% 
F I G U R E  2  Macroscopic appearance 
and orientation of collagen fibers of 
decellularized matrices. Macroscopic 
aspects were observed after the different 
tendon tissue decellularization treatments, as 
indicated, for shape and coloration (Gross). 
SR staining shows the corresponding 
orientation of preserved collagen fibers. 
Scale bars: 100 μm. SR: Sirius Red 
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t‐test was used to compare mean results with control ten-
dons. Biomechanical properties of tendon samples origi-
nating from the same (n = 7) and different (n = 10) tendon 
tissues were pooled to represent control values.
2.6 | Tendon matrix recellularization
Reseeding of hFTPs and cytocompatibility were assessed 
on decellularized matrices, which included an additional 
sterilization step with ethanol 70% for 4 hours, subsequent 
rinsing with 1X PBS three times for 20 minutes, incubation 
at 37° with standard growth medium, and finally two rinses 
in PBS to allow for cell culture. The tendon matrices were 
further cut into pieces of 10 mm × 10 mm × 1.2 mm. Each 
sample was transferred to a 24‐well plate and seeded with 
hFPTs from an established cell bank (FE002‐Ten, pas-
sages 5‐6).27 Cell suspensions were prepared with DMEM 
supplemented to 5.97 mM L‐glutamine (L‐glut: Gibco, 
ThermoFischer Scientific) with 10% FBS. Suspensions 
of 50  µL were distributed on the decellularized matrices 
to seed 105  cells or 106  cells, and 50 µL of medium was 
used for controls. Five hundred microliters of media were 
added in each well around the tendon, avoiding the surface 
where cells were deposited, after 30 minutes. The media 
was changed after 24 hours, and then, every 2‐3 days. After 
72 hours and 10 days, the samples were cut in half. Half of 
the samples were rinsed twice with PBS, fixed in forma-
lin solution for 4 hours at 37°C, washed thrice with PBS, 
dehydrated, and embedded in paraffin with orientation to 
obtain sections of depth and stained with DAPI and HE for 
histological analysis. The other half of each sample was 
used for MTT staining (3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐
dephenyltetrazolium bromide) to detect metabolic activity 
of hFTP cells. The MTT assay was done accordingly to 
the manufacturer protocol (MTT, M6494, Thermo Fisher 
Scientific). In brief, after removing the culture medium 
the samples were covered with a 10% MTT solution in 
DMEM for 4 hours at 37°C in a humidified atmosphere 
containing 5% CO2. After 4 hours, the MTT solution was 
removed and samples were rinsed with 1X PBS. Images for 
the MTT assay were taken with an iPhone 7 plus (Apple). 
For Histology, images were taken with an inverted micro-
scope equipped for fluorescence (IX81; Olympus, Tokyo, 
Japan) and a digital camera (iXon; Andor Technology Ltd., 
Belfast, United Kingdom). Each sample condition was 
tested thrice in duplicate.
3 |  RESULTS
3.1 | Macroscopic structure
Macroscopic aspects of tendon matrices were observed 
after the different decellularization treatments (Figure 2). 
Treatment with SDS 1% resulted in a shrunken matrix that 
had a consistency similar to a hard gel with visible disor-
ganization of collagen fibers within the tissue structure by 
SR staining. Tendon matrices treated with other detergent 
methods retained an approximately original shape, and no 
pink coloration due to eventual remaining vascularization 
was observed. Triton 1% appeared to preserve the structure 
of the tendon on SR, and, although some gaps appeared be-
tween fibers, the collagen remained well aligned and more 
intact than for other detergent treatments. For F/T treatments, 
the macroscopic appearance and collagen structure were well 
preserved and comparable to controls (Figure 2).
3.2 | Decellularization
The effectiveness of decellularization protocols was assessed 
by the presence of nuclei (HE), nuclei remnants (DAPI), and 
DNA content (Figure 3). A large reduction in HE staining 
of cell nuclei was observed for both detergent only and F/T 
treatments compared to controls (Figure 3A). Nuclei rem-
nants observed with HE staining for all detergent protocols 
were lower than for controls, but still detectable with DAPI. 
Triton 1% treatment of tendons was less effective on vessels, 
and some cellular material was clearly visible in these re-
gions both with HE and DAPI. Regarding F/T protocols, HE 
stainings were devoid of visible nuclei, which was further 
supported by the absence of DAPI signal for F/T+NaCl 1M 
or F/T‐Triton and, to a lesser extent, for F/T+ddH2O.
The concentration of DNA extracted from the tissues 
treated with the different protocols are shown in Figure 3B. 
Control tendons contained an average DNA quantity of 
430‐ng DNA/mg dry tissue with a high level of variation. 
Decellularization with detergents only was removed approxi-
mately 30%‐50% of DNA content, which was non‐significant. 
F/T treatments were superior to detergent treatments, re-
moving 75%, 79%, and 93% of expected DNA content, for 
F/T plus ddH20, Triton 1%, and NaCl 1M, respectively.
At this point, F/T+NaCl was selected as the leading can-
didate protocol for further investigation due to its superior 
decellularization efficiency (least amount of DNA detected) 
and preservation of morphological tendon structure. The two 
most commonly used protocols were retained for compara-
tive value (SDS 1% and Triton 1%).
3.3 | Biomechanical assessment
Biomechanical results are presented in Table 1 and Figure 4 
and show the ultimate strain (%), ultimate stress (MPa), 
Young’s modulus (MPa), and energy to failure (J) reported 
for native tendon controls and for each of the decellulariza-
tion conditions. In terms of ultimate strain, the mean was 
significantly higher for SDS 1% (11%) and F/T+NaCl 1M 
(12%), while the Triton‐treated matrices were similar to 
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F I G U R E  3  DNA content of tendons following decellularization. A, HE and DAPI staining of tendon sections after decellularization with 
indicated protocols. Nuclei are seen in purple with HE, and DAPI staining shows DNA content in blue. HE: hematoxylin and eosin, DAPI:  
4ʹ,6‐diamidino‐2‐phenylindole. Scale bars: 100 μm. B, Amount of DNA recovered from tendon matrices with different decellularization protocols 
(ng/mg). *Significant differences from the mean of control experiments were determined by Student’s t‐tests (P < .005). Extractions were done in 
triplicate 
(A)
(B)
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controls. The mean  ultimate stress for F/T+NaCl was the 
highest at 16.66 MPa, which was significantly higher than 
for controls (9.3 MPa) or detergent‐treated tendons. None 
of the decellularization treatments significantly affected the 
Young’s modulus compared to control tissues, which had 
an average of 122 MPa. Tendon matrices treated with SDS 
1% obtained a slightly lower value of 119 MPa, whereas 
F/T+NaCl treatment reached an average value of 140 MPa. 
The total energy required to cause rupture of the native 
tissue and tendon matrices was again significantly higher for 
tendons decellularized with F/T+NaCl treatment. A mean of 
<1 J was required to break control tendons; higher values 
were found for F/T+NaCl (2 J).
3.4 | Reseeding with hFTPs
Recellularization with hFPTs was visible with HE and MTT 
staining for Triton 1% and F/T+NaCl tendon matrices after 72 
Protocol Strain (%) Stress (MPa) Young (Mpa) E calc (J)
Control 8.09% ± 1.54 7.95 ± 3.12 122.25 ± 50.78 0.86 ± 0.34
SDS 1% 11.11% ± 1.97a 9.93 ± 3.18 118.79 ± 30.78 1.07 ± 0.35
Triton 1% 8.77% ± 2.72 8.77 ± 2.72 116.39 ± 45.83 0.94 ± 0.29
F/T+NaCl 1M 11.86% ± 5.69a 16.66 ± 7.41a 140.22 ± 51.90 1.83 ± 0.82a
aValue significantly different from controls. 
T A B L E  1  Biomechanical tensil results
F I G U R E  4  Biomechanical property testing with native control and decellularized tendon. Mean values for ultimate strain (%), ultimate stress 
(MPa), Young’s modulus (MPa), and energy to failure (J) of tissues after different decellularized protocols (Triton 1%, SDS 1%, F/T‐NaCl 1M). 
*Significant differences from controls were determined by Student’s t-tests
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hours and 10 days (Figure 5A,B). No cells were visible for SDS‐
treated or control matrices at either time point (Figure 5A,B). 
Reseeded cells remained rather superficial after 72 hours; but 
after 10 days, we have found that several cells infiltrate the 
matrices up to 300 microns for both conditions (Figure 5A). A 
higher inoculum of 106 cells produced a significantly more effi-
cient recellularization of matrices than 105 cells after 72 hours, 
although after 10 days this difference was not observable, as 
indicated by the darker MTT staining, but had a lesser effect 
on Triton‐treated tendons (Figure 5B). Additionally, F/T+NaCl 
decellularized matrices appeared to have a higher MTT inten-
sity than those treated with Triton, therefore suggesting that 
cells may more easily integrate the scaffold (Figure 5B).
4 |  DISCUSSION
In this study, we identified a simplified, effective decellulari-
zation protocol for SDFT to be considered for hand tendon 
grafting with appropriate sizes of matrix. Processing should 
allow a proper decellularization of the tissue to diminish 
the risk of host immune reaction, as well as preserve bio-
mechanical properties and support cell viability. F/T cycles 
combined with Triton 1% have previously been shown to be 
more effective than detergents alone for decellularization of 
SDFT, which was also supported by our results.16 This is the 
first report of using hypertonic NaCl 1M instead of detergent 
with F/T cycles to achieve a properly decellularized tendon 
F I G U R E  5  Decellularized tendon matrices after reseeding with 105 and 106 hFPTs. Tendon matrices previously decellularized with SDS 1%, 
Triton 1%, or F/T NaCl 1M were reseeded with hFPTs (0, 105 and 106 cells) and processed for (A) histology with HE stain and (B) MTT staining at 
72 hours and 10 days. Control tendons where no hFPTs were added were imaged at 10 days 
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matrix with good biomechanical properties and cytocompat-
ibility. Other protocols tested in this study were included in 
order to compare results with commonly used methods in a 
standardized manner, as results are known to vary greatly be-
tween studies.
Decellularization was evaluated by the presence of cells 
(HE) or nuclei (DAPI) and the total amount of DNA remain-
ing after treatment. While HE staining allowed the detection 
of cells and their distribution within the tissue, DAPI was 
more sensitive to detect remaining DNA. Detergents alone in 
this study were able to reduce detectable DNA by ~50%‐70%, 
which is slightly lower than previously reported for deter-
gent decellularization.16,37,38 F/T were the only protocols 
where nuclei were not detectable, and the concentration of 
recovered DNA was dramatically reduced, particularly for 
F/T+NaCl‐treated matrices, to the point where almost no 
DNA was detected. F/T cycles combined with Triton have 
reported decreases of ~80%‐87% residual DNA,16 which is 
in line with the percentages reported here. The only protocol 
near the threshold of 20 ng/mg, which has been proposed as 
an acceptable definition of an efficient decellularization, was 
F/T+NaCl 1M at ~30 ng/mg representing a 93% removal of 
DNA content.20
Tendons generally have an off‐white, silver color with a 
dense and fibrous appearance. A conservative protocol should 
not impact macroscopic aspects, as alterations would possi-
bly reduce the biomechanical properties of the tendon. The 
observed shrinkage and rigidity of tendons following SDS 
treatment indicated that this protocol is not well suited for the 
development a force‐resistant matrix, which was further con-
firmed by biomechanical testing. Other detergents allowed a 
better preservation of the macroscopic structure, both visibly 
and microscopically through SR staining of collagen fiber 
orientation. However, the best results were again obtained 
with F/T+NaCl treatment, where the tendon retained similar 
aspects to controls.
Biomechanical properties of tendon matrices are very im-
portant as these materials are destined to be grafted and will 
need to sustain and transmit forces in the hand while avoiding 
reruptures. We show here that decellularized tendon matrix 
obtained by F/T+NaCl 1M had comparable or higher values 
of strain, stress, modulus, and energy to rupture to native con-
trol tendons and was superior to other treatment protocols. 
The ultimate stress value is of high importance as to prevent 
premature tendon rupture, and F/T+NaCl matrices were able 
to bear higher tensile forces than control tendons. The higher 
strain value found with F/T+NaCl treatment would permit 
further deformation of the matrix before breakage. Modulus 
is also of high importance for hand tendon reconstruction, as 
a low modulus translates into low rigidity and higher elas-
ticity. If a flexor or an extensor of the hand is grafted with a 
more elastic material than native tissue, it will be difficult to 
initiate fine, precise, and rapid movements with the affected 
finger, as muscle contraction force will be lost in tendon elas-
tic elongation. The strong biomechanical properties observed 
for F/T+NaCl decellularized tendon matrices compared to 
native tendons indicates that they would be excellent candi-
dates for further clinical development.
The F/T protocol produced resulting matrices with more 
robust features than with only detergent methods tested 
here, but also many commercial products available for ten-
don treatment. Indeed, Aurora et al4 reviewed mean Young’s 
modulus between 15.2 and 40.1 MPa for most tested prod-
ucts (Restore, CuffPatch, GraftJacket and TissueMend). 
Only AlloPatch presented a higher rigidity with a Young’s 
modulus of 304. Our scaffolds were also more rigid and re-
sistant than those obtained by Youngstrom et al, which were 
also from equine SDFT. Their samples of 400 μm in depth 
presented a Young’s modulus of approximately 70‐76 MPa 
and maximum stress of 6 MPa for the treated and untreated 
samples, respectively.17 In comparison, our scaffolds were 
slightly more resistant at equally corrected cross sections.
The addition of hFPTs for tendon recellularization 
would be a potential way to improve tendon matrices for 
grafting, as hFTPs would be progressively replaced by host 
tissue after surgical placement, leading to an improved 
integration and better healing response.19 To date, stud-
ies of reseeding SDFT have used equine adipose‐derived 
mesenchymal stromal cells,16,29,39 which are a promising 
cellular therapy for veterinary medicine, but would be not 
suitable for human cellular therapy. Human fetal cells such 
as hFTPs are not only able to stimulate healing, but they 
are also highly proliferative and can be used to create cell 
banks for a consistent, safe clinical therapy.27 Additionally, 
they are already predefined cells, unlike stem cells, and do 
not de‐differentiate.
Surface reseeding with hFTPs was successful for both 
Triton 1% and F/T+NaCl treated matrices, visible at both 
short and prolonged time intervals. Cells were able to infil-
trate both treated matrices after 10 days, but F/T NaCl matri-
ces showed a stronger MTT staining indicating that presence 
of a higher quantity of cells after 10 days. Even if penetration 
of hFTPs was slightly deeper in regions where the ECM was 
more disorganized, we observed that cells were able to infil-
trate the matrices up to 300 microns under both conditions. 
Injection within the mid‐substance of the scaffolds or the 
creation of small holes by needle puncture could also help 
for better distribution of cellular therapies within the ma-
trix structure,40,41 but the impact of such techniques on the 
mechanical properties remains to be verified. Alternatively, 
mechanical stimulation by stretching of reseeded tendons 
could further induce tenogenic differentiation and cellu-
lar alignment that may improve tendon healing.39 Overall, 
both HE and MTT staining indicated that the F/T+NaCl 1M 
protocol was biocompatible and allowed sterile cell culture, 
proving promising for future clinical development.
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Decellularized tendon matrices would realistically need to 
be tailored for any size of injury. To replace hand flexor or ex-
tensor tendons, an adapted size would be a minimum of 3 mm 
in diameter and 15 cm in length.42 The decellularized tendon 
matrices tested here were smaller than what would be used 
in tendon reconstruction in order to favor reproducibility and 
be thin enough that the treatment could reach all the tissue in 
the same manner. However, vascular zones showed high cel-
lularity, and it is possible that with the small quantities used 
here, high variability in DNA content occurred due to random 
selection of zones that were more vascularized than others. 
To optimize the protocols further, digestion should be done 
on larger pieces to avoid risks of small zone selection bias.
5 |  CONCLUSION
Overall, we were able to develop a simple and efficient protocol 
for the decellularization of equine SDFT using F/T+NaCl 1M. 
The use of NaCl has the advantage of easy leeching from 
tissues during the washing steps with less residual product 
remaining in the matrix that could be a cause for cellular tox-
icity, as potentiated with the use of strong detergents. The 
ability to automate F/T decellularization has recently been 
documented,29 which, combined with the use of biocompat-
ible GMP‐grade human cellular therapies presented here, fur-
ther supports the development of decellularized SDFT as a 
future clinical solution for human tendon surgery indications.
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